Haemolytic disease of the newborn

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 2, 2007, Pages

  Murray, Neil A ^a   Roberts, Irene A G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; IMMUNOGLOBULIN; MATERNAL ANTIBODY; PYRUVATE KINASE;

ALPHA THALASSEMIA; ANTIBODY SCREENING; BLOOD EXAMINATION; BLOOD GROUP ABO SYSTEM; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHROCYTE DISORDER; ERYTHROCYTE MEMBRANE; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; HEMOGLOBINOPATHY; HEMOLYSIS; HEREDITARY SPHEROCYTOSIS; HUMAN; HYPERBILIRUBINEMIA; NEWBORN HEMOLYTIC DISEASE; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW;

ABO BLOOD-GROUP SYSTEM; ANEMIA, HEMOLYTIC, CONGENITAL; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTE MEMBRANE; HEMOGLOBINOPATHIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PHOTOTHERAPY; PRENATAL DIAGNOSIS;

EID: 33947227544     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2005.076794     Document Type: Review

References (53)

1. Wang m, Hays T, Ambruso DR, et al. Hemolytic disease of the newborn caused by a high titer anti-group B IgG from a group A mother. Pediatr Blood Cancer 2005;45:861-2.
2. Chen JY, Ling UP. Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility. Zhonghua Yi Xue Za Zhi (Taipei) 1994;53:13-18.
3. Oski FA. The erythrocyte and its disorders. In: Nathan A, Oski FA, eas. Hematology of infancy and childhood. Philadelphia: WB Saunders, 1993:18-43.
4. Waldron P, de Alarcon P. ABO hemolytic disease of the newborn: a unique constellation of findings in siblings and review of protective mechanisms in the fetal-maternal system. Am J Perinatol 1999;16:391-8.
5. Ziprin JH, Payne E, Hamidi L, et al. ABO incompatibility due to immunoglobulin G anti-B antibodies presenting with severe fetal anaemia. Transfus Med 2005;15:57-60.
6. Palek J, Jarolim P. Clinical expression and laboratory detection of red blood cell membrane protein mutations. Semin Hematol 1993;30:249-83.
7. Delaunay J. Molecular basis of red cell membrane disorders. Acta Haematol 2002;108:210-18.
8. Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol 1999;104:2-13.
9. Luzzatto L. Glucose-6-phosphate dehydrogenase deficiency. In: Nathan A, Oski FA, eds. Hematology of infancy and childhood.4th edn. Philadelphia: WB Saunders, 1993:674-95.
10. Kaplan M. Genetic interactions in the pathogenesis of neonatal hyperbilirubinemia: Gilbert's Syndrome and glucose-6-phosphate dehydrogenase deficiency. J Perinatol 2001;21(Suppl 1):S35-9.
11. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a potential source of severe neonatal hyperbilirubinaemia and kernicterus. Semin Neonatol 2002;7:121-8.
12. www.rialto.com/favism/english/index.mv (accessed 9 Jan 2007).
13. Gilsanz F, Vega MA, Gomez-Castillo E, et al. Fetal anaemia due to pyruvate kinase deficiency. Arch Dis Child 1993;69:523-4.
14. Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: from genetics to clinical manifestations. Bailliere's Best Pract Res Clin Haematol 2000;13:57-81.
15. Schneider AS. Triosephosphate isomerase deficiency: historical perspectives and molecular aspects. Bailliere's Best Pract Res Clin Haematol 2000;13:119-40.
16. Davies SC, Cronin E, Gill M, et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess. 2000;4: iii-v, 1-99).
17. Higgs DR. Alpha-thalassaemia. Bailliere's Clin Haematol 1993;6:117-50.
18. Chik KW, Shing MM, Li CK, et al. Treatment of hemoglobin Bart's hydrops with bone marrow transplantation. J Pediatr 1998;132:1039-42.
19. Sohan K, Billington M, Pamphilon D, et al. Normal growth and development following in utero diagnosis and treatment of homozygous alpha-thalassaemia. BJOG 2002;109:1308-10.
20. Lee-Potter JP, Deacon-Smith RA, Simpkiss MJ, et al. A new cause of hemolytic anemia in the newborn. J Clin Pathol 1975;28:317-20.
21. Howard H, Martlew V, McFadyen I, et al. Consequences for fetus and neonate of maternal red cell alloimmunisation. Arch Dis Child Fetal Neonatal Ed 1998;78:F62-6.
22. Stockman JA, de Alarcon PA. Overview of the state of the art of Rh disease: history, current clinical management, and recent progress. J Pediatr Hematol Oncol 2001;23:385-93.
23. Thompson J. Haemolytic disease of the newborn: the new NICE guidelines. J Fam Health Care 2002;12:133-6.
24. Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998;338:798-803.
25. Bennett PR, Le Van Kim C, Colin Y, et al. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med, 1993 26, 329:607-10.
26. Al-Mufti R, Howard C, Overton T, et al. Detection of fetal messenger ribonucleic acid in maternal blood to determine fetal RhD status as a strategy for noninvasive prenatal diagnosis. Am J Obstet Gynecol 1998;179:210-4.
27. Bianchi DW, Avent ND, Costa JM, et al. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol 2005;106:841-4.
28. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000;14:44-61.
29. Harkness UF, Spinnato JA. Prevention and management of RhD isoimmunization. Clin Perinatol 2004;31:721-42.
30. Yaseen H, Khalaf M, Rashid N, et al. Does prophylactic phototherapy prevent hyperbilirubinemia in neonates with ABO incompatibility and positive Coombs' test? J Perinatol 2005;25:590-4.
31. Newman TB, Liljestrand, PJeremy RJ, et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med, 2006;4, 354:1889-900.
32. van Kamp IL, Klumper FJ, Meerman RH, et al. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand 2004;83:731-7.
33. Murray NA, Roberts IA. Neonatal transfusion practice. Arch Dis Child Fetal Neonatal Ed 2004;89:F101-7.
34. Dinesh D. Review of positive direct antiglobulin tests found on cord blood sampling. J Paediatr Child Health 2005;41:504-7.
35. Cortey A, Brossard Y. [Adverse effects and patient information]. J Gynecol Obstet Biol Reprod (Paris) 2006;35(1 Suppl):1S112-1S118.
36. Cremer RJ, Perryman PW, Richards DH. Influence of light on the hyperbilirubinaemia of infants. Lancet, 1958 24, 1(7030):1094-7.
37. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol 2004;28:326-33.
38. Hart G, Cameron R. The importance of irradiance and area in neonatal phototherapy. Arch Dis Child Fetal Neonatal Ed 2005;90:F437-40.
39. Vreman HJ, Wong RJ, Stevenson DK, et al. Light-emitting diodes: a novel light source for phototherapy. Pediatr Res 1998;44:804-9.
40. Seidman DS, Moise J, Ergaz Z, et al. A prospective randomized controlled study of phototherapy using blue and blue-green light-emitting devices, and conventional halogen-quartz phototherapy. J Perinatol 2003;23:123-7.
41. Thaithumyanon P, Visutiratmanee C. Double phototherapy in jaundiced term infants with hemolysis. J Med Assoc Thai 2002;85:1176-81.
42. McDonagh AF. Phototherapy: from ancient Egypt to the new millennium. J Perinatol 2001;21(Suppl 1):S7-S12.
43. Miqdad AM, Abdelbasit OB, Shaheed MM, et al. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 2004;16:163-6.
44. Mukhopadhyay K, Murki S, Narang A, et al. Intravenous immunoglobulins in rhesus hemolytic disease. Indian J Pediatr 2003;70:697-9.
45. Alpay F, Sarici SU, Okutan V, et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999;88:216-9.
46. Dagoglu T, Ovali F, Samanci N, et al. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995;23:264-71.
47. Voto LS, Sexer H, Ferreiro G, et al. Neonatal administration of high-dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med 1995;23:443-51.
48. Rubo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992;121:93-7.
49. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002;3:CD003313.
50. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003;88:F6-10.
51. Hayakawa F, Imada K, Towatari M, et al. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002;118:1187-9.
52. Quinti I, Pierdominici M, Marziali M, et al. European surveillance of immunoglobulin safety - results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002;104:231-6.
53. Dennery PA. Metalloporphyrins for the treatment of neonatal jaundice. Curr Opin Pediatr 2005;17:167-9.